Exenatide Modifier With Branched PEG Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current exenatide modifiers for treating diabetes have short durations of action and require frequent injections, leading to patient burden and compliance issues, with existing modifications often reducing GLP-1 receptor agonistic activities and stability.
Innovation Solution
Development of exenatide modifiers with hydrophilic linking arms, specifically aliphatic chains with terminal carboxyl groups or ether-containing chains, to enhance pharmacokinetic properties and prolong hypoglycemic effects while maintaining high GLP-1 receptor agonistic activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If exenatide is modified with simple PEG, then half-life is extended, but drug activity decreases
Solution Approach 1:
The patent applies parameter changes by modifying the PEG structure from simple linear chains to branched structures with specific parameters: branch number (1-10), branch length (1-20 units), and molecular weight (1k-10k Da). These parameter optimizations maintain drug activity while extending half-life, resolving the contradiction between duration extension and activity preservation.
Solution Approach 2:
The patent creates composite modification structures by combining multiple PEG branches with the exenatide core molecule. The branched PEG architecture integrates hydrophilic properties for stability with optimized spatial configuration for receptor binding, achieving both extended half-life and maintained activity through composite material design.
2Reliability
If injection frequency is increased to maintain efficacy, then blood glucose control improves, but patient burden increases
Solution Approach 1:
The patent applies dynamics by creating a modification system that adapts to physiological conditions. The branched PEG structure provides dynamic balance between drug release rate and receptor binding affinity, enabling sustained blood glucose control over extended periods while reducing injection frequency and patient burden.
3Stability of the object's composition
If protein drug stability is improved through modification, then degradation resistance increases, but drug activity decreases
Solution Approach 1:
The patent applies local quality by strategically placing PEG branches at specific locations on the exenatide molecule. The branched PEG structure provides localized protection against degradation at critical regions while preserving the active pharmacophore regions for receptor binding, thus maintaining both stability and activity.
Data Source
AI summary
Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.